Oct12019UncategorizedCategory: UncategorizedBy Charlotte Maddalena1 October 2019 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Baikowski® hereby confirms its acquisition of Mathym SAS, a company with which it commenced negotiations in July 2019NextNext post:First-in-class immune checkpoint inhibitor to be presented at SITCRelated PostsOrphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency18 November 2024ORPHELIA Pharma collaborates with Oscar Lambret clinical center11 June 2024ORPHELIA Pharma recrute un/une Chef de Projet Réglementaire Senior7 June 2024ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024Six new projects supported by our Foundation18 March 2024
Orphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency18 November 2024
ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024
Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024
